Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Mar;33(3):275–280. doi: 10.1111/j.1365-2125.1992.tb04035.x

Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias.

U M Birgersdotter 1, W Wong 1, J Turgeon 1, D M Roden 1
PMCID: PMC1381275  PMID: 1576047

Abstract

1. Recent reports have indicated a role for the P450IID6 polymorphism in the stereoselective disposition of single doses of the antiarrhythmic flecainide. 2. In this study, we evaluated the effects of adding low dose quinidine, a potent inhibitor of P450IID6, to chronic flecainide therapy in patients with arrhythmias. 3. In five extensive metabolizer patients, quinidine significantly reduced the clearance of R-(-)-flecainide, from 395 +/- 121 (s.d.) to 335 +/- 88 ml min-1. This change was attributable to a decrease in metabolic clearance, was accompanied by decreased formation of the two major metabolites of flecainide and was not observed in a poor metabolizer subject. The renal clearance of R-(-)-flecainide rose significantly. 4. Quinidine did not alter the clearance of S-(+)-flecainide. 5. The pharmacologic effects of flecainide therapy (QRS widening, % arrhythmia suppression) were slightly, but not significantly, increased. 6. In extensive metabolizer patients receiving chronic flecainide, increased plasma concentrations will develop if P450IID6 is inhibited.

Full text

PDF
275

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brinn R., Brøsen K., Gram L. F., Haghfelt T., Otton S. V. Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol. 1986 Aug;22(2):194–197. doi: 10.1111/j.1365-2125.1986.tb05250.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brøsen K., Gram L. F., Haghfelt T., Bertilsson L. Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol. 1987 Apr;60(4):312–314. doi: 10.1111/j.1600-0773.1987.tb01758.x. [DOI] [PubMed] [Google Scholar]
  3. Carey E. L., Jr, Duff H. J., Roden D. M., Primm R. K., Wilkinson G. R., Wang T., Oates J. A., Woosley R. L. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest. 1984 Feb;73(2):539–547. doi: 10.1172/JCI111241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Chiou W. L. Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve. J Pharmacokinet Biopharm. 1978 Dec;6(6):539–546. doi: 10.1007/BF01062108. [DOI] [PubMed] [Google Scholar]
  5. Dayer P., Balant L., Kupfer A., Striberni R., Leemann T. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol. 1985;28(3):317–320. doi: 10.1007/BF00543330. [DOI] [PubMed] [Google Scholar]
  6. Elharrar V., Zipes D. P. Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers. J Pharmacol Exp Ther. 1982 Feb;220(2):440–447. [PubMed] [Google Scholar]
  7. Evans D. A., Mahgoub A., Sloan T. P., Idle J. R., Smith R. L. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980 Apr;17(2):102–105. doi: 10.1136/jmg.17.2.102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Funck-Brentano C., Kroemer H. K., Pavlou H., Woosley R. L., Roden D. M. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol. 1989 Apr;27(4):435–444. doi: 10.1111/j.1365-2125.1989.tb05391.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Funck-Brentano C., Turgeon J., Woosley R. L., Roden D. M. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther. 1989 Apr;249(1):134–142. [PubMed] [Google Scholar]
  10. Gross A. S., Mikus G., Fischer C., Hertrampf R., Gundert-Remy U., Eichelbaum M. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol. 1989 Nov;28(5):555–566. doi: 10.1111/j.1365-2125.1989.tb03542.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Guehler J., Gornick C. C., Tobler H. G., Almquist A., Schmid J. R., Benson D. W., Jr, Benditt D. G. Electrophysiologic effects of flecainide acetate and its major metabolites in the canine heart. Am J Cardiol. 1985 Mar 1;55(6):807–812. doi: 10.1016/0002-9149(85)90161-4. [DOI] [PubMed] [Google Scholar]
  12. Inaba T., Tyndale R. E., Mahon W. A. Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol. 1986 Aug;22(2):199–200. doi: 10.1111/j.1365-2125.1986.tb05251.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Kroemer H. K., Funck-Brentano C., Silberstein D. J., Wood A. J., Eichelbaum M., Woosley R. L., Roden D. M. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation. 1989 May;79(5):1068–1076. doi: 10.1161/01.cir.79.5.1068. [DOI] [PubMed] [Google Scholar]
  14. Kroemer H. K., Turgeon J., Parker R. A., Roden D. M. Flecainide enantiomers: disposition in human subjects and electrophysiologic actions in vitro. Clin Pharmacol Ther. 1989 Nov;46(5):584–590. doi: 10.1038/clpt.1989.189. [DOI] [PubMed] [Google Scholar]
  15. Lee J. T., Kroemer H. K., Silberstein D. J., Funck-Brentano C., Lineberry M. D., Wood A. J., Roden D. M., Woosley R. L. The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 1990 Jun 21;322(25):1764–1768. doi: 10.1056/NEJM199006213222502. [DOI] [PubMed] [Google Scholar]
  16. Mahgoub A., Idle J. R., Dring L. G., Lancaster R., Smith R. L. Polymorphic hydroxylation of Debrisoquine in man. Lancet. 1977 Sep 17;2(8038):584–586. doi: 10.1016/s0140-6736(77)91430-1. [DOI] [PubMed] [Google Scholar]
  17. Mikus G., Gross A. S., Beckmann J., Hertrampf R., Gundert-Remy U., Eichelbaum M. The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther. 1989 May;45(5):562–567. doi: 10.1038/clpt.1989.73. [DOI] [PubMed] [Google Scholar]
  18. Morganroth J., Anderson J. L., Gentzkow G. D. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol. 1986 Sep;8(3):607–615. doi: 10.1016/s0735-1097(86)80190-5. [DOI] [PubMed] [Google Scholar]
  19. Munafo A., Biollaz J. High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serum. J Chromatogr. 1989 May 30;490(2):450–457. doi: 10.1016/s0378-4347(00)82805-4. [DOI] [PubMed] [Google Scholar]
  20. Roden D. M., Duff H. J., Altenbern D., Woosley R. L. Antiarrhythmic activity of the O-demethyl metabolite of encainide. J Pharmacol Exp Ther. 1982 Jun;221(3):552–557. [PubMed] [Google Scholar]
  21. Siddoway L. A., Thompson K. A., McAllister C. B., Wang T., Wilkinson G. R., Roden D. M., Woosley R. L. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation. 1987 Apr;75(4):785–791. doi: 10.1161/01.cir.75.4.785. [DOI] [PubMed] [Google Scholar]
  22. Speirs C. J., Murray S., Boobis A. R., Seddon C. E., Davies D. S. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol. 1986 Dec;22(6):739–743. doi: 10.1111/j.1365-2125.1986.tb02969.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Turgeon J., Funck-Brentano C., Gray H. T., Pavlou H. N., Prakash C., Blair I. A., Roden D. M. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers. Clin Pharmacol Ther. 1991 May;49(5):488–496. doi: 10.1038/clpt.1991.59. [DOI] [PubMed] [Google Scholar]
  24. Turgeon J., Kroemer H. K., Prakash C., Blair I. A., Roden D. M. Stereoselective determination of flecainide in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci. 1990 Feb;79(2):91–95. doi: 10.1002/jps.2600790202. [DOI] [PubMed] [Google Scholar]
  25. Turgeon J., Pavlou H. N., Wong W., Funck-Brentano C., Roden D. M. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. J Pharmacol Exp Ther. 1990 Nov;255(2):642–649. [PubMed] [Google Scholar]
  26. Walle T., Walle U. K., Olanoff L. S., Conradi E. C. Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol. 1986 Sep;22(3):317–323. doi: 10.1111/j.1365-2125.1986.tb02893.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Woosley R. L., Roden D. M., Dai G. H., Wang T., Altenbern D., Oates J., Wilkinson G. R. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther. 1986 Mar;39(3):282–287. doi: 10.1038/clpt.1986.40. [DOI] [PubMed] [Google Scholar]
  28. Zhou H. H., Anthony L. B., Roden D. M., Wood A. J. Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther. 1990 Jun;47(6):686–693. doi: 10.1038/clpt.1990.94. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES